Y-4 tables
Phase 2Small molecule
Y-4 tables is one of 43 small molecule programs targeting Postherpetic Neuralgia. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
69 competitors in Postherpetic Neuralgia
#DrugCompanyPhaseTrials
1Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Bayer Aspirin
BayerApproved
Lamictal
GGlaxo Dba Glaxosmithkline
Approved
Ketalar
AAultman Health Foundation
Approved
Osmitrol
BB. Braun Medical Inc.
Approved
Neurontin
VViatris Specialty LLC
Phase 3
Dolophine
HHikma Pharmaceuticals LLC
Phase 3
Pamelor
SSpecgx
Phase 3
Norpramin
VValidus Pharmaceuticals
Phase 3
MS Contin
HHikma Pharmaceuticals LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tics1 trial
Safety and Pharmacokinetics of Y-4 Tablets in Healthy Subjects
Recruiting·—·Phase 1·NCT06935682·36 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Y-4 tables. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details